{"ticker": {"uuid": "eb64bade-4c9e-49a5-a30d-539ebca2200e", "symbol": "AMRX", "name": "Amneal Pharmaceuticals, Inc. Class A Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?", "summary": "Amneal Pharmaceuticals AMRX completed its acquisition of Kashiv BioSciences on Monday, creating an integrated global biosimilars platform spanning research, development, manufacturing and commercialization. The deal broadens Amneal's biosimilar capabilities as it seeks more consistent launches. The investment case still depends on integration, regulatory execution and product uptake. Amneal Gains an End-to-End Biosimilar Platform Kashiv adds development and manufacturing capabilities to Amneal's existing commercialization platform. Bringing those functions together is intended to support a ste", "url": "https://finance.yahoo.com/healthcare/articles/amneals-kashiv-deal-turn-biosimilars-155300977.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:53:00+00:00", "published_display": "12 Aug 2026 15:53", "sentiment": "positive", "sentiment_pct": 87, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.282, "duplicate_count": 1, "topics": ["Biosimilars", "Biotech", "Fda", "M A", "Pharma"]}, {"title": "Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?", "summary": "Amneal Pharmaceuticals AMRX enters the second half of 2026 with higher guidance and a broader product pipeline. The company is expanding complex generics, biosimilars and specialty medicines while adjusted earnings and EBITDA improve. The trade-off is clear. Rytary has lost exclusivity, generic pricing remains competitive and complex launches carry regulatory and adoption risk. Valuation also sends a mixed signal, making execution central to the buy case. AMRX's 2026 Outlook Keeps Moving Higher Amneal raised 2026 net revenue guidance to $3.10-$3.20 billion from $3.05-$3.15 billion. Adjusted EB", "url": "https://finance.yahoo.com/markets/stocks/articles/amrx-stock-buy-growth-improves-155100927.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:51:00+00:00", "published_display": "12 Aug 2026 15:51", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.351, "duplicate_count": 1, "topics": ["Biosimilars", "Earnings", "Guidance", "Pharma", "Specialty Medicines"]}, {"title": "AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?", "summary": "Amneal Pharmaceuticals AMRX shares have gained 44.8% over the past 12 weeks, putting the durability of the advance in focus. The rally has coincided with better operating results and a higher 2026 outlook. The next leg will depend on whether earnings growth, new launches and pipeline progress can outweigh execution risks and a valuation that has moved well above AMRX's own historical norm. AMRX's Earnings Momentum Supports the Rally Second-quarter 2026 revenues rose 10% year over year to $796 million, topping the Zacks Consensus Estimate of $768 million. Adjusted earnings increased 20% to 30 c", "url": "https://finance.yahoo.com/markets/stocks/articles/amrx-stock-surges-44-8-154900846.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:49:00+00:00", "published_display": "12 Aug 2026 15:49", "sentiment": "positive", "sentiment_pct": 87, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.351, "duplicate_count": 1, "topics": ["Earnings", "Earnings Estimate", "Earnings Growth", "Earnings Per Share", "Fda Approval", "Generics"]}, {"title": "KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema", "summary": "Kodiak Sciences KOD announced that it initiated a global late-stage ALTO study evaluating KSI-501 in patients with diabetic macular edema (DME). KSI-501 is an investigational bispecific therapy that targets IL-6 and VEGF for the treatment of retinal vascular diseases. Patient enrollment is ongoing. DME is a complex, multi-factorial condition in which vascular leakage, disruption of the blood-retinal barrier, and chronic inflammatory signaling collectively contribute to retinal edema and vision loss. Year to date, Kodiak's shares have risen 55.2% compared with the industry's 6% growth.Zacks Inv", "url": "https://finance.yahoo.com/healthcare/articles/kod-begins-stage-study-ksi-151500677.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T15:15:00+00:00", "published_display": "11 Aug 2026 15:15", "sentiment": "positive", "sentiment_pct": 84, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.286, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Earnings", "Earnings Per Share", "Retinal Diseases"]}, {"title": "Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why", "summary": "Most of us have heard the dictum \"the trend is your friend.\" And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- that could keep the momentum in the stock going. Our \"Recent Price Strength\" screen, w", "url": "https://finance.yahoo.com/markets/stocks/articles/amneal-amrx-great-choice-trend-125502842.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T12:55:02+00:00", "published_display": "11 Aug 2026 12:55", "sentiment": "positive", "sentiment_pct": 90, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.382, "duplicate_count": 1, "topics": ["Earnings", "Earnings Estimate", "Pharma", "Price Target"]}, {"title": "1 Healthcare Stock Worth Your Attention and 2 We Ignore", "summary": "1 Healthcare Stock Worth Your Attention and 2 We Ignore From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 18.3% over the past six months, topping the S&P 500 by 7.4 percentage points. Although these businesses have produced results, only a handful will thrive over the long term as the influx of venture capital has ushered in a new wave of competition. Taking that into account, here is one healthcare stock poised to generate sus", "url": "https://finance.yahoo.com/healthcare/articles/1-healthcare-stock-worth-attention-124522652.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T12:45:22+00:00", "published_display": "10 Aug 2026 12:45", "sentiment": "neutral", "sentiment_pct": 45, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.132, "duplicate_count": 1, "topics": ["Earnings Per Share", "Healthcare", "Pharmaceuticals", "Telemedicine"]}], "by_tier": {"direct": [{"title": "Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?", "summary": "Amneal Pharmaceuticals AMRX completed its acquisition of Kashiv BioSciences on Monday, creating an integrated global biosimilars platform spanning research, development, manufacturing and commercialization. The deal broadens Amneal's biosimilar capabilities as it seeks more consistent launches. The investment case still depends on integration, regulatory execution and product uptake. Amneal Gains an End-to-End Biosimilar Platform Kashiv adds development and manufacturing capabilities to Amneal's existing commercialization platform. Bringing those functions together is intended to support a ste", "url": "https://finance.yahoo.com/healthcare/articles/amneals-kashiv-deal-turn-biosimilars-155300977.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:53:00+00:00", "published_display": "12 Aug 2026 15:53", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 87, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.282, "duplicate_count": 1, "topics": ["Biosimilars", "Biotech", "Fda", "M A", "Pharma"]}, {"title": "Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?", "summary": "Amneal Pharmaceuticals AMRX enters the second half of 2026 with higher guidance and a broader product pipeline. The company is expanding complex generics, biosimilars and specialty medicines while adjusted earnings and EBITDA improve. The trade-off is clear. Rytary has lost exclusivity, generic pricing remains competitive and complex launches carry regulatory and adoption risk. Valuation also sends a mixed signal, making execution central to the buy case. AMRX's 2026 Outlook Keeps Moving Higher Amneal raised 2026 net revenue guidance to $3.10-$3.20 billion from $3.05-$3.15 billion. Adjusted EB", "url": "https://finance.yahoo.com/markets/stocks/articles/amrx-stock-buy-growth-improves-155100927.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:51:00+00:00", "published_display": "12 Aug 2026 15:51", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.351, "duplicate_count": 1, "topics": ["Biosimilars", "Earnings", "Guidance", "Pharma", "Specialty Medicines"]}, {"title": "AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?", "summary": "Amneal Pharmaceuticals AMRX shares have gained 44.8% over the past 12 weeks, putting the durability of the advance in focus. The rally has coincided with better operating results and a higher 2026 outlook. The next leg will depend on whether earnings growth, new launches and pipeline progress can outweigh execution risks and a valuation that has moved well above AMRX's own historical norm. AMRX's Earnings Momentum Supports the Rally Second-quarter 2026 revenues rose 10% year over year to $796 million, topping the Zacks Consensus Estimate of $768 million. Adjusted earnings increased 20% to 30 c", "url": "https://finance.yahoo.com/markets/stocks/articles/amrx-stock-surges-44-8-154900846.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:49:00+00:00", "published_display": "12 Aug 2026 15:49", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 87, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.351, "duplicate_count": 1, "topics": ["Earnings", "Earnings Estimate", "Earnings Growth", "Earnings Per Share", "Fda Approval", "Generics"]}, {"title": "KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema", "summary": "Kodiak Sciences KOD announced that it initiated a global late-stage ALTO study evaluating KSI-501 in patients with diabetic macular edema (DME). KSI-501 is an investigational bispecific therapy that targets IL-6 and VEGF for the treatment of retinal vascular diseases. Patient enrollment is ongoing. DME is a complex, multi-factorial condition in which vascular leakage, disruption of the blood-retinal barrier, and chronic inflammatory signaling collectively contribute to retinal edema and vision loss. Year to date, Kodiak's shares have risen 55.2% compared with the industry's 6% growth.Zacks Inv", "url": "https://finance.yahoo.com/healthcare/articles/kod-begins-stage-study-ksi-151500677.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T15:15:00+00:00", "published_display": "11 Aug 2026 15:15", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 84, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.286, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Earnings", "Earnings Per Share", "Retinal Diseases"]}, {"title": "Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why", "summary": "Most of us have heard the dictum \"the trend is your friend.\" And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- that could keep the momentum in the stock going. Our \"Recent Price Strength\" screen, w", "url": "https://finance.yahoo.com/markets/stocks/articles/amneal-amrx-great-choice-trend-125502842.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T12:55:02+00:00", "published_display": "11 Aug 2026 12:55", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 90, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.382, "duplicate_count": 1, "topics": ["Earnings", "Earnings Estimate", "Pharma", "Price Target"]}, {"title": "1 Healthcare Stock Worth Your Attention and 2 We Ignore", "summary": "1 Healthcare Stock Worth Your Attention and 2 We Ignore From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 18.3% over the past six months, topping the S&P 500 by 7.4 percentage points. Although these businesses have produced results, only a handful will thrive over the long term as the influx of venture capital has ushered in a new wave of competition. Taking that into account, here is one healthcare stock poised to generate sus", "url": "https://finance.yahoo.com/healthcare/articles/1-healthcare-stock-worth-attention-124522652.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T12:45:22+00:00", "published_display": "10 Aug 2026 12:45", "provider": "eodhd", "sentiment": "neutral", "sentiment_pct": 45, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.132, "duplicate_count": 1, "topics": ["Earnings Per Share", "Healthcare", "Pharmaceuticals", "Telemedicine"]}], "industry": [], "sector": []}, "total_fetched": 6, "total_unique": 6, "total_relevant": 6, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 6}, "raw_articles": 6, "unique_stories": 6, "duplicates_removed": 0, "relevant_stories": 6, "current_evidence": 6, "direct_evidence": 6, "eodhd_articles": 6, "eodhd": {"configured": true, "status": "healthy", "calls_used": 340, "call_budget": 500, "budget_used_pct": 68.0, "requests_made": 68, "last_success_at": "2026-08-13T12:45:18.490737+00:00", "newest_seen_at": "2026-08-13T12:29:05+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 2767, "unmapped_mentions": 2040}, "status": "healthy"}, "sentiment_summary": {"positive": 5, "negative": 0, "neutral": 1, "score": 73, "raw_score": 83, "total": 6, "evidence_count": 6, "effective_articles": 5.57, "direct_story_count": 6, "industry_story_count": 0, "sector_story_count": 0, "story_count": 6, "source_count": 1, "source_concentration": 1.0, "direct_share": 100, "dispersion": 11, "confidence": 72, "evidence_status": "measured", "score_version": "evidence-v4", "newest_article_at": "2026-08-12T15:53:00+00:00", "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 73, "events": [{"event": "earnings", "label": "Earnings", "weight": 2.4, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 0.6, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.6, "count": 1}], "positive_events": 5, "negative_events": 0, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 6}, "raw_articles": 6, "unique_stories": 6, "duplicates_removed": 0, "relevant_stories": 6, "current_evidence": 6, "direct_evidence": 6, "eodhd_articles": 6, "eodhd": {"configured": true, "status": "healthy", "calls_used": 340, "call_budget": 500, "budget_used_pct": 68.0, "requests_made": 68, "last_success_at": "2026-08-13T12:45:18.490737+00:00", "newest_seen_at": "2026-08-13T12:29:05+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 2767, "unmapped_mentions": 2040}, "status": "healthy"}}, "market_context": {"has_market_context": true, "latest_close": 18.14, "latest_week": "2026-08-07", "one_week_move": -1.0, "four_week_move": 6.6, "twelve_week_move": 52.1, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.088344, "market_dynamics_buy_signal": false, "relative_strength": 23.388951, "fair_value_gap": 104.5, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 57.9088, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.0% over one week, +6.6% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Positive news being faded", "tone": "negative", "classification": "positive_rejected", "summary": "Constructive headlines are not being rewarded by price, which raises a rejection flag.", "confidence": 83, "badges": ["Sentiment confirms active trend", "Positive but stretched"], "opportunities": ["Constructive tone aligns with the Sharemaestro trend signal."], "risks": ["Constructive tone is arriving with price materially above fair value."], "event_label": "Earnings", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "finance.yahoo.com", "count": 6}], "tiers": [{"label": "Direct company coverage", "count": 6}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 4}, {"label": "Deals and strategy", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "73/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Evidence confidence", "value": "72/100", "tone": "positive", "text": "5.57 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "Positive news being faded", "tone": "negative", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}, {"label": "Primary event", "value": "Earnings", "tone": "positive", "text": "73/100 classification confidence."}, {"label": "Company focus", "value": "6", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "11/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-1.0% over one week, +6.6% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?"}], "updated_at": "2026-08-13T12:56:13.345913+00:00", "detail_intelligence": {"headline": "Positive news being faded", "summary": "Constructive news tone is drawn from 6 fresh independent stories, including 6 company-specific items across 1 publishers.", "status": "measured", "metrics": [{"label": "Weighted tone", "value": 73, "display": "73", "tone": "positive", "note": "Constructive news tone"}, {"label": "Evidence confidence", "value": 72, "display": "72", "tone": "positive", "note": "solid confidence"}, {"label": "Company focus", "value": 100, "display": "100%", "tone": "positive", "note": "6 direct stories"}, {"label": "Evidence agreement", "value": 89, "display": "89", "tone": "positive", "note": "11/100 dispersion"}], "confidence_drivers": [{"label": "Sample depth", "value": 70, "note": "5.57 effective stories"}, {"label": "Source breadth", "value": 20, "note": "1 independent publishers"}, {"label": "Direct relevance", "value": 100, "note": "company-specific evidence share"}, {"label": "Freshness", "value": 80, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 89, "note": "cross-story consistency"}, {"label": "Source independence", "value": 0, "note": "lower publisher concentration"}], "freshness": 80, "source_independence": 0, "timeline": [{"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 87.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 133.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 0, "score": null, "tone": "neutral", "x": 179.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 225.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 271.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 0, "score": null, "tone": "neutral", "x": 316.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-31", "label": "31 Jul", "count": 0, "score": null, "tone": "neutral", "x": 362.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 408.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 0, "score": null, "tone": "neutral", "x": 454.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 0, "score": null, "tone": "neutral", "x": 500.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 545.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 591.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 637.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 0, "score": null, "tone": "neutral", "x": 683.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-08", "label": "08 Aug", "count": 0, "score": null, "tone": "neutral", "x": 729.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 0, "score": null, "tone": "neutral", "x": 774.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 1, "score": 45, "tone": "neutral", "x": 820.6, "y": 144.1, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-08-11", "label": "11 Aug", "count": 2, "score": 87, "tone": "positive", "x": 866.4, "y": 67.7, "volume_height": 34.7, "volume_y": 231.3}, {"date": "2026-08-12", "label": "12 Aug", "count": 3, "score": 85, "tone": "positive", "x": 912.2, "y": 71.3, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-13", "label": "13 Aug", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "820.6,144.1 866.4,67.7 912.2,71.3", "timeline_has_signal": true, "timeline_start": "24 Jul", "timeline_mid": "03 Aug", "timeline_end": "13 Aug", "momentum": {"label": "Establishing", "tone": "neutral", "recent_score": 83, "prior_score": null, "delta": null, "recent_count": 6, "prior_count": 0, "volume_delta": 6}, "freshness_buckets": [{"label": "Last 24 hours", "count": 3, "share": 50}, {"label": "1 to 3 days", "count": 3, "share": 50}, {"label": "4 to 7 days", "count": 0, "share": 0}, {"label": "8 to 30 days", "count": 0, "share": 0}], "source_profile": [{"label": "finance.yahoo.com", "count": 6, "share": 100, "score": 83, "tone": "positive"}], "event_profile": [{"label": "Earnings", "count": 4, "share": 67, "score": 82, "tone": "positive"}, {"label": "Deals and strategy", "count": 1, "share": 17, "score": 87, "tone": "positive"}, {"label": "Regulatory and legal", "count": 1, "share": 17, "score": 84, "tone": "positive"}], "topics": [{"label": "Earnings", "count": 4, "share": 67}, {"label": "Pharma", "count": 3, "share": 50}, {"label": "Earnings Per Share", "count": 3, "share": 50}, {"label": "Earnings Estimate", "count": 2, "share": 33}, {"label": "Biotech", "count": 2, "share": 33}, {"label": "Biosimilars", "count": 2, "share": 33}, {"label": "Telemedicine", "count": 1, "share": 17}, {"label": "Specialty Medicines", "count": 1, "share": 17}, {"label": "Retinal Diseases", "count": 1, "share": 17}, {"label": "Price Target", "count": 1, "share": 17}], "supporting": [{"label": "Direct evidence", "text": "6 current stories are mapped specifically to AMRX."}, {"label": "Narrative agreement", "text": "Cross-story agreement is 89/100, indicating a comparatively coherent tape."}], "tempering": [{"label": "Source breadth", "text": "Only 1 publisher currently contribute to the measured read."}, {"label": "Price disagreement", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}], "supporting_heading": "What supports the read", "tempering_heading": "What tempers the read", "latest_observation": {"title": "Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?", "summary": "Amneal Pharmaceuticals AMRX completed its acquisition of Kashiv BioSciences on Monday, creating an integrated global biosimilars platform spanning research, development, manufacturing and commercialization. The deal broadens Amneal's biosimilar capabilities as it seeks more consistent launches. The investment case still depends on integration, regulatory execution and product uptake. Amneal Gains an End-to-End Biosimilar Platform Kashiv adds development and manufacturing capabilities to Amneal's existing commercialization platform. Bringing those functions together is intended to support a ste", "url": "https://finance.yahoo.com/healthcare/articles/amneals-kashiv-deal-turn-biosimilars-155300977.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:53:00+00:00", "published_display": "12 Aug 2026 15:53", "sentiment": "positive", "sentiment_pct": 87, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.287, "duplicate_count": 1, "topics": ["Biosimilars", "Biotech", "Fda", "M A", "Pharma"]}, "article_count": 6, "updated_at": "2026-08-13T10:33:39.923756+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 135.8, "label": "13 Feb 2026", "close": 14.82, "index": 100.0}, {"x": 78.6, "y": 143.1, "label": "20 Feb 2026", "close": 14.5, "index": 97.8}, {"x": 115.2, "y": 158.9, "label": "27 Feb 2026", "close": 13.81, "index": 93.2}, {"x": 151.7, "y": 172.0, "label": "06 Mar 2026", "close": 13.24, "index": 89.3}, {"x": 188.3, "y": 204.2, "label": "13 Mar 2026", "close": 11.83, "index": 79.8}, {"x": 224.9, "y": 204.2, "label": "20 Mar 2026", "close": 11.83, "index": 79.8}, {"x": 261.5, "y": 203.7, "label": "27 Mar 2026", "close": 11.85, "index": 80.0}, {"x": 298.0, "y": 189.3, "label": "03 Apr 2026", "close": 12.48, "index": 84.2}, {"x": 334.6, "y": 188.0, "label": "10 Apr 2026", "close": 12.54, "index": 84.6}, {"x": 371.2, "y": 156.6, "label": "17 Apr 2026", "close": 13.91, "index": 93.9}, {"x": 407.8, "y": 188.4, "label": "24 Apr 2026", "close": 12.52, "index": 84.5}, {"x": 444.3, "y": 181.3, "label": "01 May 2026", "close": 12.83, "index": 86.6}, {"x": 480.9, "y": 172.9, "label": "08 May 2026", "close": 13.2, "index": 89.1}, {"x": 517.5, "y": 201.9, "label": "15 May 2026", "close": 11.93, "index": 80.5}, {"x": 554.1, "y": 190.7, "label": "22 May 2026", "close": 12.42, "index": 83.8}, {"x": 590.7, "y": 173.6, "label": "29 May 2026", "close": 13.17, "index": 88.9}, {"x": 627.2, "y": 160.3, "label": "05 Jun 2026", "close": 13.75, "index": 92.8}, {"x": 663.8, "y": 104.3, "label": "12 Jun 2026", "close": 16.2, "index": 109.3}, {"x": 700.4, "y": 104.0, "label": "19 Jun 2026", "close": 16.21, "index": 109.4}, {"x": 737.0, "y": 80.7, "label": "26 Jun 2026", "close": 17.23, "index": 116.3}, {"x": 773.5, "y": 82.6, "label": "03 Jul 2026", "close": 17.15, "index": 115.7}, {"x": 810.1, "y": 85.8, "label": "10 Jul 2026", "close": 17.01, "index": 114.8}, {"x": 846.7, "y": 66.6, "label": "17 Jul 2026", "close": 17.85, "index": 120.4}, {"x": 883.3, "y": 65.0, "label": "24 Jul 2026", "close": 17.92, "index": 120.9}, {"x": 919.8, "y": 55.8, "label": "31 Jul 2026", "close": 18.32, "index": 123.6}, {"x": 956.4, "y": 59.9, "label": "07 Aug 2026", "close": 18.14, "index": 122.4}], "sentiment_points": [{"x": 718.5, "y": 113.4, "label": "22 Jun 2026", "score": 59}, {"x": 719.2, "y": 113.4, "label": "22 Jun 2026", "score": 59}, {"x": 719.6, "y": 111.6, "label": "22 Jun 2026", "score": 60}, {"x": 719.9, "y": 113.4, "label": "22 Jun 2026", "score": 59}, {"x": 720.3, "y": 113.4, "label": "22 Jun 2026", "score": 59}, {"x": 720.4, "y": 113.4, "label": "22 Jun 2026", "score": 59}, {"x": 720.7, "y": 113.4, "label": "22 Jun 2026", "score": 59}, {"x": 721.0, "y": 113.4, "label": "22 Jun 2026", "score": 59}, {"x": 725.3, "y": 113.4, "label": "23 Jun 2026", "score": 59}, {"x": 726.0, "y": 113.4, "label": "23 Jun 2026", "score": 59}, {"x": 726.4, "y": 113.4, "label": "23 Jun 2026", "score": 59}, {"x": 727.0, "y": 113.4, "label": "24 Jun 2026", "score": 59}, {"x": 727.3, "y": 113.4, "label": "24 Jun 2026", "score": 59}, {"x": 729.3, "y": 113.4, "label": "24 Jun 2026", "score": 59}, {"x": 730.9, "y": 113.4, "label": "24 Jun 2026", "score": 59}, {"x": 732.7, "y": 113.4, "label": "25 Jun 2026", "score": 59}, {"x": 733.7, "y": 111.6, "label": "25 Jun 2026", "score": 60}, {"x": 734.3, "y": 111.6, "label": "25 Jun 2026", "score": 60}, {"x": 734.6, "y": 111.6, "label": "25 Jun 2026", "score": 60}, {"x": 734.9, "y": 111.6, "label": "25 Jun 2026", "score": 60}, {"x": 743.0, "y": 109.8, "label": "27 Jun 2026", "score": 61}, {"x": 746.6, "y": 111.6, "label": "27 Jun 2026", "score": 60}, {"x": 747.1, "y": 111.6, "label": "27 Jun 2026", "score": 60}, {"x": 749.3, "y": 111.6, "label": "28 Jun 2026", "score": 60}, {"x": 750.8, "y": 111.6, "label": "28 Jun 2026", "score": 60}, {"x": 759.8, "y": 113.4, "label": "30 Jun 2026", "score": 59}, {"x": 764.8, "y": 113.4, "label": "01 Jul 2026", "score": 59}, {"x": 770.8, "y": 113.4, "label": "02 Jul 2026", "score": 59}, {"x": 772.6, "y": 113.4, "label": "02 Jul 2026", "score": 59}, {"x": 774.2, "y": 113.4, "label": "03 Jul 2026", "score": 59}, {"x": 776.2, "y": 111.6, "label": "03 Jul 2026", "score": 60}, {"x": 782.0, "y": 111.6, "label": "04 Jul 2026", "score": 60}, {"x": 795.6, "y": 111.6, "label": "07 Jul 2026", "score": 60}, {"x": 796.4, "y": 111.6, "label": "07 Jul 2026", "score": 60}, {"x": 806.9, "y": 109.8, "label": "09 Jul 2026", "score": 61}, {"x": 815.3, "y": 111.6, "label": "10 Jul 2026", "score": 60}, {"x": 856.9, "y": 109.8, "label": "18 Jul 2026", "score": 61}, {"x": 857.2, "y": 107.9, "label": "19 Jul 2026", "score": 62}, {"x": 863.7, "y": 107.9, "label": "20 Jul 2026", "score": 62}, {"x": 867.6, "y": 107.9, "label": "20 Jul 2026", "score": 62}, {"x": 870.9, "y": 107.9, "label": "21 Jul 2026", "score": 62}, {"x": 874.1, "y": 107.9, "label": "22 Jul 2026", "score": 62}, {"x": 874.9, "y": 107.9, "label": "22 Jul 2026", "score": 62}, {"x": 880.1, "y": 107.9, "label": "23 Jul 2026", "score": 62}, {"x": 888.3, "y": 106.1, "label": "24 Jul 2026", "score": 63}, {"x": 905.3, "y": 109.8, "label": "28 Jul 2026", "score": 61}, {"x": 912.8, "y": 111.6, "label": "29 Jul 2026", "score": 60}, {"x": 913.5, "y": 111.6, "label": "29 Jul 2026", "score": 60}, {"x": 921.6, "y": 113.4, "label": "31 Jul 2026", "score": 59}, {"x": 925.5, "y": 111.6, "label": "01 Aug 2026", "score": 60}, {"x": 934.3, "y": 113.4, "label": "02 Aug 2026", "score": 59}, {"x": 958.0, "y": 113.4, "label": "07 Aug 2026", "score": 59}], "price_path": "42.0,135.8 78.6,143.1 115.2,158.9 151.7,172.0 188.3,204.2 224.9,204.2 261.5,203.7 298.0,189.3 334.6,188.0 371.2,156.6 407.8,188.4 444.3,181.3 480.9,172.9 517.5,201.9 554.1,190.7 590.7,173.6 627.2,160.3 663.8,104.3 700.4,104.0 737.0,80.7 773.5,82.6 810.1,85.8 846.7,66.6 883.3,65.0 919.8,55.8 956.4,59.9", "sentiment_path": "718.5,113.4 719.2,113.4 719.6,111.6 719.9,113.4 720.3,113.4 720.4,113.4 720.7,113.4 721.0,113.4 725.3,113.4 726.0,113.4 726.4,113.4 727.0,113.4 727.3,113.4 729.3,113.4 730.9,113.4 732.7,113.4 733.7,111.6 734.3,111.6 734.6,111.6 734.9,111.6 743.0,109.8 746.6,111.6 747.1,111.6 749.3,111.6 750.8,111.6 759.8,113.4 764.8,113.4 770.8,113.4 772.6,113.4 774.2,113.4 776.2,111.6 782.0,111.6 795.6,111.6 796.4,111.6 806.9,109.8 815.3,111.6 856.9,109.8 857.2,107.9 863.7,107.9 867.6,107.9 870.9,107.9 874.1,107.9 874.9,107.9 880.1,107.9 888.3,106.1 905.3,109.8 912.8,111.6 913.5,111.6 921.6,113.4 925.5,111.6 934.3,113.4 958.0,113.4", "price_change": 22.4, "sentiment_change": 0, "latest_close": 18.14, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug"}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}